CYDY
CytoDyn Inc.·Healthcare
0.29
0.138%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.2052W H: $0.45
CYDY NEWS
globenewswire.com
Mar 24
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma
globenewswire.com
Mar 5
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
VANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has closed on a financing of $17.5 million in gross proceeds, with Paulson Investment Company acting as placement agent. The demand from both new and current investors highlights confidence in CytoDyn's clinical progress and its versatile development strategy in immuno-oncology, exploring a number of potential roles for leronlimab – the Company's first-in-class humanized monoclonal antibody that targets the CCR5 receptor.
globenewswire.com
Feb 20
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretreated mTNBC Patients VANCOUVER, Washington, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”), today announced that new preclinical, translational, and clinical data supporting leronlimab's proposed role in the treatment of metastatic triple-negative breast cancer was presented at the AACR Immuno-Oncology Conference (AACR IO), held February 18-21, 2026 in Los Angeles, California. Leronlimab is being evaluated for its ability to modulate the tumor immune microenvironment by targeting the CCR5 receptor, a key regulator of immune function implicated in cancer progression and immune resistance.
defenseworld.net
Feb 13
Head-To-Head Review: BeOne Medicines (NASDAQ:ONC) versus CytoDyn (OTCMKTS:CYDY)
CytoDyn (OTCMKTS:CYDY - Get Free Report) and BeOne Medicines (NASDAQ: ONC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability. Profitability This table compares CytoDyn and BeOne Medicines' net
defenseworld.net
Feb 10
Ironwood Pharmaceuticals (NASDAQ:IRWD) & CytoDyn (OTCMKTS:CYDY) Critical Survey
CytoDyn (OTCMKTS:CYDY - Get Free Report) and Ironwood Pharmaceuticals (NASDAQ: IRWD - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends. Risk and Volatility CytoDyn has a beta of
globenewswire.com
Jan 27
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that a compassionate benefactor has formally committed funding to support the Company's Expanded Access Program (EAP) for patients with triple-negative breast cancer. The benefactor, who has chosen to remain anonymous, has a longstanding interest in patient access initiatives, the potential of leronlimab, and how the Company's recent data and mechanism of action theories might serve to offer experimental avenues to patients who have exhausted all approved treatment options.
